loader image
Thursday, February 26, 2026
65.8 F
McAllen
- Advertisement -

Urging caution on AI in mammography

Translate to Spanish or other 102 languages!

Doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment. Newswise Image
Doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment. Newswise Image

Mega Doctor News

- Advertisement -

 By University of California, Los Angeles (UCLA), Health Sciences 

Newswise — Analyzing breast-cancer tumors with artificial intelligence has the potential to improve healthcare efficiency and outcomes. But doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment.

That’s according to a new editorial in JAMA Health Forum co-written by Joann G. Elmore, MD, MPH, a researcher at the UCLA Jonsson Comprehensive Cancer Center, the Rosalinde and Arthur Gilbert Foundation Endowed Chair in Health Care Delivery and professor of medicine at the David Geffen School of Medicine at UCLA.

- Advertisement -

“Without a more robust approach to the evaluation and implementation of AI, given the unabated adoption of emergent technology in clinical practice, we are failing to learn from our past mistakes in mammography,” the JAMA Health Forum editorial states. The piece, posted online Friday, was co-written with Christoph I. Lee, MD, MS, MBA, a professor of radiology at the University of Washington School of Medicine.

One of those “past mistakes in mammography,” according to the authors, was adjunct computer-aided detection (CAD) tools, which grew rapidly in popularity in the field of breast cancer screening starting more than two decades ago. CAD was approved by the FDA in 1998, and by 2016 more than 92% of U.S. imaging facilities were using the technology to interpret mammograms and hunt for tumors. But the evidence showed CAD did not improve mammography accuracy. “CAD tools are associated with increased false positive rates, leading to overdiagnosis of ductal carcinoma in situ and unnecessary diagnostic testing,” the authors wrote. Medicare stopped paying for CAD in 2018, but by then the tools had racked up more than $400 million a year in unnecessary health costs.

“The premature adoption of CAD is a premonitory symptom of the wholehearted embrace of emergent technologies prior to fully understanding their impact on patient outcomes,” Elmore and Lee wrote.

The doctors suggest several safeguards to put in place to avoid “repeating past mistakes,” including tying Medicare reimbursement to “improved patient outcomes, not just improved technical performance in artificial settings.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

New Study Reveals Why Eczema Commonly Appears in Early Childhood

A team of researchers at the Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, and other institutions have uncovered a key biological explanation for why eczema so often starts in childhood.

Parents’ Obesity Linked to Higher Liver Disease Risk in Adult Children

A new study from researchers at Washington University School of Medicine in St. Louis shows that a person’s risk of developing one of the most common chronic liver disorders is strongly correlated to the level of obesity of their parents.

How to Get Ahead of Spring Allergies Before They Start

Mega Doctor News CLEVELAND CLINIC - Spring may still be a ways off,...

Texas Medical Board opens applications for new physician license pathways under DOCTOR Act

The Texas Medical Board has begun accepting applications for two new physician license categories created by House Bill 2038, known as the DOCTOR Act, expanding pathways for internationally trained physicians and medical school graduates who did not secure residency positions.
- Advertisement -